Press Releases Events & Presentations Press Releases Year None20202019201820172016201520142013201220112010 Sep 04, 2020 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version Aug 28, 2020 Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020 View HTML PDF Version Aug 27, 2020 Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection View HTML PDF Version Aug 07, 2020 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version Aug 05, 2020 Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights View HTML PDF Version Jul 20, 2020 Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection View HTML PDF Version Jul 09, 2020 Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection View HTML PDF Version Jul 02, 2020 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version Jun 25, 2020 Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection View HTML PDF Version Jun 22, 2020 Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II View HTML PDF Version Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Shareholder Tools Print Email Alerts Printed Materials RSS News Feeds Search Investors
Press Releases Year None20202019201820172016201520142013201220112010 Sep 04, 2020 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version Aug 28, 2020 Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020 View HTML PDF Version Aug 27, 2020 Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection View HTML PDF Version Aug 07, 2020 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version Aug 05, 2020 Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights View HTML PDF Version Jul 20, 2020 Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection View HTML PDF Version Jul 09, 2020 Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection View HTML PDF Version Jul 02, 2020 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version Jun 25, 2020 Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection View HTML PDF Version Jun 22, 2020 Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II View HTML PDF Version Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
